Tech Center 1600 • Art Units: 1614 1618
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17274284 | COMPOSITIONS CONTAINING LINOLEIC ACID | Final Rejection | MARS, INCORPORATED |
| 18022670 | COMPOSITION COMPRISING POLYETHYLENE GLYCOL CONJUGATED TO INDOCYANINE GREEN AND METHODS OF USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17998761 | CARBON NANOTUBES AND COMPLEXES THEREOF FOR TREATING AND DETECTING OCULAR TUMORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18997563 | LONG-ACTING LOW-TOXICITY NOVEL CATIONIC LIPID COMPOUNDS AND COMPOSITION THEREOF | Non-Final OA | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| 18272110 | CAVITATION AGENT | Non-Final OA | Oxford University Innovation Limited |
| 18260775 | Labeling precursors and radiotracers for nuclear medicine diagnosis and therapy of prostate cancer-induced bone metastases | Non-Final OA | SCV-SpezialChemikalienVertrieb GmbH |
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | Non-Final OA | Transcode Therapeutics, Inc. |
| 18259000 | A PLATFORM TO OBTAIN MONOCLONAL ANTIBODIES DIRECTED AGAINST PROCESSED TUMOR-SPECIFIC ANTIGENS | Non-Final OA | Mediterranea Theranostic srl |
| 18209972 | OSSEOINTEGRATIVE IMPLANTS | Final Rejection | CTL Medical Corporation |
| 18094898 | METHODS OF MAKING PROSTATE CANCER TREATMENT DECISIONS | Non-Final OA | Progenics Pharmaceuticals, Inc. |
| 18082421 | LIQUID COMPOSITIONS COMPRISING A SUSTAINED RELEASE SYSTEM FOR INSECTICIDES | Non-Final OA | Terramera Exco Holdings Ltd. |
| 18010498 | CONJUGATED AND LABELLED APELIN, PREPARATION AND USES THEREOF | Non-Final OA | ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE |
| 17571065 | SPINOSYN FORMULATIONS FOR TREATMENT OF DEMODEX-INDUCED OCULAR AND FACIAL CONDITIONS | Non-Final OA | APERTA BIOSCIENCES, LLC |
| 17615302 | EXTRACELLULAR VESICLES FOR DELIVERING THERAPEUTIC OR DIAGNOSTIC DRUGS | Non-Final OA | FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy